Eugia gets USFDA warning letter for Unit-3 in Pashamylaram
Eugia Pharma is a wholly-owned subsidiary of Hyderabad-based drug manufacturer, Aurobindo Pharma
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Aurobindo Pharma
Eugia Pharma gets USFDA nod for posaconazole injection, 300 mg/16.7 mL, single-dose vial
The approved product has an estimated market size of $25.4 million for the twelve months ending October 2023, according to IQVIA
Fortifying Brand India Pharma
Lessons and insights on measures and approaches to drive innovation, quality and growth in India's pharma sector from industry…
Evive, Acrotech get FDA nod for Ryzneuta (Efbemalenograstim alfa Injection) for chemo-induced…
Neutropenia is characterised by persistently low levels of neutrophils due to the use of chemotherapy and other types of…
Tergene Biotech gets CDSCO’s recommendation for PCV15 vaccine
The PCV15 vaccine has been developed by Tergene Biotech and manufactured at AuroVaccines, a wholly-owned subsidiary of Aurobindo…
Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US
The licensing pact has been inked between Evive and Acrotech Biopharma (Acrotech), a New Jersey-based and wholly-owned subsidiary…
Eugia Pharma receives US FDA nod for Amphotericin B Liposome Injection
Has an estimated market size of around US$ 145 million for the 12 months ending September 2022, according to IQVIA.
Aurobindo units recall products in US market for manufacturing issues
The affected lot of the medication, which is used to treat high blood pressure, has been manufactured in India and marketed in the…
Aurobindo Pharma subsidiary’s plant gets one observation from US FDA
The plant is owned by Aurolife Pharma, a wholly-owned step down subsidiary of the company
Aurobindo Pharma’s Andhra unit gets three US FDA observations
The company will respond to the FDA within the stipulated timeline and work closely with the regulator to address the observations…